Spero Therapeutics (SPRO) and GSK (GSK) said Wednesday that a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met its primary endpoint and will end early due to efficacy.
Shares of Spero catapulted 228% as intraday trading volume soared to over 166.9 million from a daily average of about 131,000.
Signing Day Sports (SGN) said Wednesday that it has signed a definitive business combination agreement to buy One Blockchain, the operating affiliate company of data hosting firm BlockchAIn Digital Infrastructure.
Shares of Signing Day soared 178%, with intraday trading volume at over 153.2 million compared with a daily average of roughly 1.7 million.
Aspire Biopharma (ASBP) said Wednesday it expects to launch Buzz Bomb, its sublingual pre-workout supplement, in Q3.
Shares surged 148% as intraday trading volume advanced to more than 567.3 million from a daily average of about 739,000.
Price: 2.24, Change: +1.56, Percent Change: +228.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.